Indo US Bio-Tech Limited reported a standalone net profit of ₹3.04 crore for the quarter ended June 30, 2026, marking a 35% decline from ₹4.70 crore in Q1FY25. While revenue from operations grew by 7% to ₹32.99 crore from ₹30.77 crore year-on-year, the profit contraction highlights margin pressure from rising production expenses and finance costs. The Board of Directors approved the unaudited financial results on August 12, 2026, following review by the Audit Committee.

The company’s total income for the quarter stood at ₹33.11 crore, up from ₹30.77 crore in Q1FY25. Other income contributed ₹12.38 lakh, a significant increase from ₹1.5 lakh in the corresponding period last year. However, total expenses rose to ₹30.03 crore from ₹25.95 crore, primarily due to higher production expenses and changes in inventory valuation.

Financial Performance Overview

Production expenses surged to ₹86.26 lakh in Q1FY26 compared to ₹88.40 lakh in Q1FY25, but this was offset by favorable changes in inventories of finished goods and work-in-progress, which reduced cost of sales by ₹12.16 lakh versus an addition of ₹6.13 lakh in the prior year. Purchase of stock-in-trade decreased significantly to ₹52.42 lakh from ₹71.51 lakh, indicating efficient inventory management or lower procurement needs.

Finance costs increased to ₹7.39 lakh from ₹4.51 lakh, reflecting higher interest outlays. Employee benefits expense remained stable at ₹3.29 lakh. Depreciation and amortization charges rose slightly to ₹2.69 lakh from ₹2.00 lakh. Other expenses declined to ₹26.69 lakh from ₹28.56 lakh, showing some control over discretionary spending.

What the Numbers Show

The divergence between revenue growth (7%) and expense growth (15.7%) reveals underlying operational inefficiencies. Although production volumes may have increased, leading to higher revenue, the associated costs did not scale proportionally. The sharp rise in finance costs suggests increased leverage or higher interest rates impacting profitability. Despite these headwinds, the company maintained positive net income, demonstrating resilience in its seed cultivation, processing, and trading business segment.

Tax expense for the quarter was ₹3.96 lakh, lower than ₹11.75 lakh in Q1FY25, partly due to deferred tax adjustments. Basic earnings per share stood at ₹1.51, down from ₹2.35 in the previous year. The statutory auditors, Bhagat & Associates, issued a limited review report with an unmodified opinion, confirming compliance with Ind-AS 34 and SEBI Listing Regulations.

Indo US Bio-Tech Limited reported a net profit of ₹3.04 crore for the quarter ended June 30, 2026, a 35% increase from ₹4.70 crore in the corresponding quarter of FY26. Revenue from operations grew 7% year-on-year to ₹32.99 crore, driven by steady demand in its seed cultivation, processing, and trading segment. The improvement in profitability was primarily aided by a significant reduction in employee benefit expenses, which turned negative in the prior year due to reversals, stabilizing operational costs in the current period.

The Board of Directors, at a meeting held on August 12, 2026, approved the unaudited standalone financial results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and received a limited review report from Bhagat & Associates, the statutory auditors, who expressed an unmodified opinion on the financial statements.

Financial Performance Highlights

*Note: Total expenses calculation includes Purchase of stock (₹524.19 lakh), Production Expenses (₹862.55 lakh), Employee Benefits (₹1,215.96 lakh), Finance Costs (₹32.94 lakh), Depreciation (₹73.93 lakh), and Other Expenses (₹26.89 lakh). The source table lists "Total Expenses" as ₹266.90 lakh before a subsequent line item of ₹3,003.35 lakh, which aligns with the sum of individual expense categories minus the negative impact of inventory changes or specific accounting adjustments not explicitly detailed in the summary rows. The profit before tax is derived as Total Income (₹3,311.05 lakh) less Total Expenses (₹3,003.35 lakh).

Revenue from operations stood at ₹3,298.68 lakh, compared to ₹3,076.96 lakh in Q1FY26. Other income increased significantly to ₹12.38 lakh from ₹0.15 lakh in the prior year. Production expenses rose to ₹862.55 lakh from ₹883.95 lakh in the same quarter last year, indicating stable cost management in core activities. However, employee benefit expenses recorded at ₹1,215.96 lakh contrasted with a credit of ₹(1,907.58) lakh in Q1FY26, reflecting a normalization of costs after prior-period adjustments.

What the Numbers Show

The divergence between revenue growth and profit decline highlights the impact of one-time items in the previous year. While revenue expanded by 7%, the profit before tax fell 36% because Q1FY26 benefited from a substantial reversal in employee benefits (₹1,907.58 lakh credit), whereas Q1FY27 incurred standard charges of ₹1,215.96 lakh. Excluding this anomaly, the underlying operational structure remains consistent, with production costs remaining relatively flat against higher sales volumes. The company continues to operate in a single major segment: Seed Cultivation, Processing & Trading.

The Board meeting commenced at 14:30 and concluded at 15:10 on August 12, 2026. There were no investor complaints pending or received during the period under review. The financial results have been prepared in accordance with Ind-AS 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013.